EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression

Robert Likić, Igor Radanović, Deni Rkman, Sanja Brnić, Gabriel Jacobs, Geert Jan Groeneveld

CNS Drugs · 04.11.2026

DOI: 10.1007/s40263-026-01346-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 04.11.2026. Verfasst von Robert Likić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, K…. Die Arbeit nennt 66 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment-resistant depression affects about one-third of patients with major depressive disorder and remains a major unmet need. Mebufotenin (5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT), the principal psychoactive constituent of Incilius alvarius parotoid secretion and of several Amazonian plants, is a pharmacologically atypical serotonergic psychedelic in clinical development for this indication. This narrative review analyses its clinical pharmacology, drawing on a structured search of PubMed/MEDLINE, EMBASE, Scopus, ClinicalTrials.gov and grey literature through 15 August 2026, supplemented by regulatory and sponsor disclosures. Mebufotenin is a non-selective serotonin agonist with high affinity at 5-hydroxytryptamine receptor 1A (5-HT1A, Ki 3.0 nM) and markedly lower affinity at 5-HT2A, with reported selectivity spanning approximately 30-fold to 300-fold depending on whether the 5-HT2A receptor is agonist- or antagonist-labelled. Clearance is dominated by monoamine oxidase A; the cytochrome P450 2D6 (CYP2D6)-derived metabolite bufotenine has a receptor profile comparable to the parent compound rather than a distinct 5-HT2A-preferring one, and was below the limit of quantification in the only human study to measure it. In the pivotal phase 2b trial (GH001-TRD-201), inhaled GH001 produced a day 8 placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction of - 15.5 points (p < 0.001; d = - 2.0) and day 8 remission in 23/40 (57.5%) versus 0/41 (0%) with placebo, with 20/23 (87.0%) day 8 remitters in remission at 6 months under as-needed retreatment and no serious treatment-related adverse events. Median psychoactive duration was 9.0-14.0 min across doses, and 97.5% of patients were discharge-ready within 1 h. GH001 has been studied without protocol-mandated psychotherapy, although this does not establish that psychological support is unnecessary. Evidence rests principally on a single randomised trial, and replication in larger, more diverse phase 3 studies with formal blinding-integrity assessment is required.

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. robert.likic@kbc-zagreb.hr.
  • Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
  • Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Croatian Institute for Health Insurance and University of Zagreb School of Medicine, Zagreb, Croatia.

Zitieren

APA

Likić, R., Radanović, I., Rkman, D., Brnić, S., Jacobs, G., & Groeneveld, G. J. (2026). From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression. CNS Drugs. https://doi.org/10.1007/s40263-026-01346-0

Vancouver

Likić R, Radanović I, Rkman D, Brnić S, Jacobs G, Groeneveld GJ. From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression. CNS Drugs. 2026. doi:10.1007/s40263-026-01346-0

BibTeX
@article{Liki2026,
  author = {Likić, Robert and Radanović, Igor and Rkman, Deni and Brnić, Sanja and Jacobs, Gabriel and Groeneveld, Geert Jan},
  title = {From Toad Venom to Drug Development: The Clinical Pharmacology of Mebufotenin (5-MeO-DMT) in Treatment-Resistant Depression},
  journal = {CNS Drugs},
  year = {2026},
  doi = {10.1007/s40263-026-01346-0}
}
Kostenlos starten →